our Premium Content: News alerts, weekly reports and conference planners

DRUG:

vocimagene amiretrorepvec/extended release flucytosine (DB107)

News alerts, weekly reports and conference planners

Company:

ApolloBio, Denovo

Drug class:

Thymidylate synthase inhibitor, Cytosine deaminase inhibitor

Related drugs:

23d

DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma (clinicaltrials.gov)

P1/2, N=70, Not yet recruiting, Nicholas Butowski | Initiation date: Sep 2024 --> Dec 2024

23 days ago

Trial initiation date • Combination therapy

MGMT (6-O-methylguanine-DNA methyltransferase)

temozolomide • vocimagene amiretrorepvec/extended release flucytosine (DB107)

4ms

Therapeutic activity of retroviral replicating vector-mediated gene therapy in combination with anti-PD-1 antibody in a murine pancreatic cancer model. (PubMed, Cancer Gene Ther)

Toca 511, a tumor-selective retroviral replicating vector encoding the yeast cytosine deaminase (yCD) gene, exerts direct antitumor effects through intratumoral prodrug 5-fluorocytosine (5-FC) conversion to active drug 5-fluorouracil by yCD, and has demonstrated therapeutic efficacy in preclinical and clinical trials of various cancers. In an orthotopic tumor and peritoneal dissemination model, the combination therapy resulted in complete regression in both transduced orthotopic tumors and untransduced peritoneal dissemination. Thus, Toca 511/5-FC treatment induced a systemic antitumor immune response, and the combination therapy could be a promising clinical strategy for treating metastatic pancreatic cancer.

4 months ago

Preclinical • Journal • Combination therapy • PD(L)-1 Biomarker • IO biomarker • Gene therapy

CD8 (cluster of differentiation 8)

5-fluorouracil • vocimagene amiretrorepvec/extended release flucytosine (DB107)

4ms

DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma (clinicaltrials.gov)

P1/2, N=70, Not yet recruiting, Nicholas Butowski

4 months ago

New P1/2 trial

MGMT (6-O-methylguanine-DNA methyltransferase)

temozolomide • vocimagene amiretrorepvec/extended release flucytosine (DB107)

7ms

DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma (clinicaltrials.gov)

P2, N=33, Recruiting, Ashish Shah | Not yet recruiting --> Recruiting

7 months ago

Enrollment open

vocimagene amiretrorepvec/extended release flucytosine (DB107)

9ms

A Biomarker-Guided Phase 2 Study of DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) Extended-Release Tablets (clinicaltrials.gov)

P2, N=33, Not yet recruiting, Ashish Shah

9 months ago

New P2 trial

vocimagene amiretrorepvec/extended release flucytosine (DB107)

over3years

Current evidence and challenges of systematic therapies for adult recurrent glioblastoma: Results from clinical trials. (PubMed, Chin J Cancer Res)

Regorafenib, rindopepimut and neoadjuvant programmed death 1 (PD-1) inhibitors are promising agents for rGBM, while regorafenib is effective in both O-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated patients. Temozolomide rechallenge and alkylating agents combined with bevacizumab can be useful for patients with MGMT methylation, and patients with isocitrate dehydrogenase (IDH) mutations or second recurrence can benefit from vocimagene amiretrorepvec (Toca 511). Some phase I trials on targeted therapy and immunotherapy have shown positive results, and results from further studies are expected. In addition to the analysis of existing clinical trial results, forthcoming trials should be well designed, and patients are encouraged to participate in appropriate clinical trials.

over 3 years ago

Clinical • Journal • PD(L)-1 Biomarker • IO biomarker

MGMT (6-O-methylguanine-DNA methyltransferase)

Avastin (bevacizumab) • temozolomide • Stivarga (regorafenib) • Rintega (rindopepimut) • vocimagene amiretrorepvec/extended release flucytosine (DB107)

4years

Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial. (PubMed, JAMA Oncol)

For the SOC control group, patients received investigators' choice of single therapy: lomustine, temozolomide, or bevacizumab. Among patients who underwent tumor resection for first or second recurrence of glioblastoma or anaplastic astrocytoma, administration of Toca 511 and Toca FC, compared with SOC, did not improve overall survival or other efficacy end points. ClinicalTrials.gov Identifier: NCT02414165.

4 years ago

Clinical • Journal • Combination therapy

IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)

Avastin (bevacizumab) • temozolomide • lomustine • vocimagene amiretrorepvec/extended release flucytosine (DB107)

almost5years

A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) (clinicaltrials.gov)

P1b, N=21, Terminated, Tocagen Inc. | N=30 --> 21 | Active, not recruiting --> Terminated; Sponsor decision

almost 5 years ago

Clinical • Enrollment change • Trial termination

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • DNMT3A (DNA methyltransferase 1) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • RB1 (RB Transcriptional Corepressor 1) • NF1 (Neurofibromin 1) • KEAP1 (Kelch Like ECH Associated Protein 1) • MGMT (6-O-methylguanine-DNA methyltransferase) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KDR (Kinase insert domain receptor) • TET2 (Tet Methylcytosine Dioxygenase 2) • KMT2D (Lysine Methyltransferase 2D) • PTCH1 (Patched 1) • MSH6 (MutS homolog 6) • CDK12 (Cyclin dependent kinase 12) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • NOTCH2 (Notch 2) • KDM6A (Lysine Demethylase 6A) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) • STAG2 (Stromal Antigen 2) • NSD1 (Nuclear Receptor Binding SET Domain Protein 1) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • SOX9 (SRY-Box Transcription Factor 9) • DICER1 (Dicer 1 Ribonuclease III) • PIK3C2B (Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Beta) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • CDKN1B (Cyclin dependent kinase inhibitor 1B) • CHD4 (Chromodomain Helicase DNA Binding Protein 4) • GATA3 (GATA binding protein 3)

IDH1 mutation • KEAP1 mutation • MGMT promoter methylation • PTCH1 mutation • STAG2 mutation • MGMT mutation

vocimagene amiretrorepvec/extended release flucytosine (DB107)